Verde Science (VRCI $.0128) Aeroponic Marijuana Growing Solutions.
View this email online if it doesn’t display correctly
Verde Science, Inc.
(OTC: VRCI)
Verde Science, Inc. is focused on Medical Marijuana Research and Development.
Verde also provides advisory services, quality assurance, and aeroponic growing systems in the burgeoning Medical Marijuana industry to established, licensed growers throughout Canada.
“New India based R&D Staff enables us to begin on research and clinical trials in India, which at the moment are on hold pending licensing in Canada.”
“This gives Verde a huge advantage.”
Assisting the Industry to Produce Premium Medical Marijuana and Cannabinoid Formulations Through Advanced Research and Development
Verde Science, Inc. (OTCQB: VRCI) has identified and developed relationships with leading research and production experts in the rapidly expanding medical marijuana industry.
The company is focused on providing an array of research and development, cannabinoid formulations, and technical services including aeroponic technology for its industry client base to enable them to produce the highest quality, greatest yield medicinal marijuana.
Verde Science supports leading-edge research to continually provide clients with a premium, branded line of medical marijuana products. Our highly experienced team is deploying state-of-the-art research and development to take a meaningful market share of the Canadian Medical Marijuana marketplace to help address a large number of health care issues.
We are being meticulous, measured and diligent as we move forward with an absolute focus on compliance while helping clients offer the patient community unsurpassed, fully integrated, holistic health care products.
The company is focused on research and development, cannabinoid formulations, and technical services including aeroponic technology for its industry client base to enable them to produce the highest quality, greatest yield medicinal marijuana.
Medicinal Marijuana
Verde Science has assembled a highly experienced, well-funded team that will deploy state-of-the-art research technology and the superior growing methodology of aeroponics to enter and take a meaningful market share. The company is launching its THC Pharmaceutical Development Program by executing a comprehensive research program which involves developing custom ?formulations preparing protocols for clinical trials which will initially be conducted through its partnership alliance with a pharmaceutical company in Mumbai, India.
Verde Science plans to develop specific, custom formulations and novel delivery mechanisms for cannabinoid and THC based drugs for a variety of ailments including chronic pain, inflammation, migraines, seizures related to epilepsy, nausea associated with cancer treatment, and numerous others. The company then plans to then conduct clinical trials in Canada after it obtains its Canadian R&D license.
With consistent, highly efficient production of clean product with no pesticides grown in environmentally friendly surroundings using recycled water, and custom cannabinoid formulations with novel delivery mechanisms, Canada will soon be introduced to the “Tesla” of medical marijuana.
Marijuana Grown with Aeroponics
Aeroponics is the process of growing plants in an air or mist environment without the use of soil or an aggregate medium (known as geoponics). The word “aeroponic” is derived from the Greek meanings of aero- (air) and ponos (labor). Aeroponic culture differs from conventional hydroponics, aquaponics, and in-vitro (plant tissue culture) growing. Unlike hydroponics, which uses a liquid nutrient solution as a growing medium and essential minerals to sustain plant growth; or aquaponics, which uses water and fish waste, aeroponics is conducted without a growing medium. Because water is used in aeroponics to transmit nutrients, it is sometimes considered a type of hydroponics.
Verde Science, Inc. expansion of its Research and Development capabilities with the addition of its newest alliance partners, Dr. Ratnesh Jain and Dr. Prajatka Dandekar Jain
Verde Science Strengthens Scientific Team
Oct 02, 2014 (ACCESSWIRE via COMTEX)
Verde Science, Inc. (VRCI-OTCQB) a Medical Marijuana Research and Development Company, is pleased to announce the expansion of its Research and Development capabilities with the addition of its newest alliance partners, Dr. Ratnesh Jain and Dr. Prajatka Dandekar Jain, both of whom earned their Ph.D.’s in Pharmacology from the Institute of Chemical Technology, a Mumbai, India based University with a research focus along the entire spectrum of Chemical Engineering. Dr. Ratnesh Jain has investigated the development and design of novel drug delivery mechanisms which we believe will have significant applications in the nascent field of Medical Marijuana treatment. This could also be applied to clinical trials aimed at determining proper dosing and drug formulations for various specific medical issues.
Dr. Prajakta Dandekar Jain is an Assistant Professor of Pharmaceutical Technology at the Institute of Chemical Technology. In addition to research into novel drug delivery systems, she has also focused much of her research on nanoparticles, which will have particular relevance in the study of medical uses of THC and cannabinoids, and nanoparticles of hemp. Harp Sangha, Verde’s Chairman and CEO commented, “The addition of Drs. Jain to our current in-house R&D staff in Canada is going to be an immediate boost to our research program. It enables us to begin on research and clinical trials in India, which at the moment are on hold pending licensing in Canada. This gives Verde a huge advantage.”
Verde’s Research and Development Program will focus on developing custom medicinal formulations from cannabinoids and THC compounds for the treatment of specific issues such as migraines, glaucoma, loss of appetite from cancer therapies, and numerous other medical issues. Verde also plans to alpha test innovate growing technologies in India as part of the company’s initiatives. (A more extensive background statement for the Drs. Jain is available on the Verde Science website: VerdeScienceInc.com
“The addition of Drs. Jain and Jain to our current in-house R&D staff in Canada is going to be an immediate boost to our research program. It enables us to begin on research and clinical trials in India, which at the moment are on hold pending licensing in Canada. This gives Verde a huge advantage.”
~Harp Sangha, Verde’s Chairman and CEO
Top Notch India Based R&D Staff could be a Huge Game Changer for VRCI!
“This gives Verde a huge advantage”
Verde Science, Inc.
(OTC: VRCI)
To Learn more about Verde Science visit the company website at:
VerdeScienceInc.com
To Subscribe to our newsletter:StockPumper.com
Please read our disclaimer at: http://stockpumper.com/review-disclaimer.php
Disclaimer – Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stockbroker before investing. You should not invest or trade in any penny stock unless are you are fully prepared, willing, able and expect to lose a hundred pct of your funds,including any profiled company or other company in any other manner mentioned or alluded to by StockPumper.com as defined in any medium whatsoever. Compensation: Five Hundred dollars for a one day awareness on VRCI from a third party.The service is provided as a guide to some available investments only, which must be tempered by the investment experience and independent decision making process of the subscriber. The accuracy of issuer documents and information that is submitted to and, its affiliated members and its management for inclusion on this site is principally the responsibility of the particular issuer and its management, its affiliated members and its management is neither responsible for, nor undertakes any steps to check, the accuracy of any information provided by featured companies to potential investors. You should confirm to your own satisfaction the veracity of any information prior to entering into any investment.